Stefan Feske, MD

Dr. Feske studied Medicine at the Universities of Hamburg and Freiburg in Germany, from where he graduated summa cum laude with a MD degree and a research thesis on Primary Immunodeficiency. After finishing his residency in the Division of Rheumatology and Clinical Immunology at the University of Freiburg, he conducted postdoctoral studies at the Max-Planck-Institute for Immunobiology (Freiburg) and the Immune Disease Institute at Harvard Medical School (Boston) in the lab of Anjana Rao. There he made essential contributions to the discovery of the CRAC channel protein ORAI1 and identified the first patients with mutations in ORAI1 and its activator STIM1 defining a new disease called CRAC channelopathy. Dr. Feske is the director of the Ion Channels & Transporters in Immunity (ICTI) program at NYU. He is a scientific co-founder of CalciMedica, a biotechnology company that develops CRAC channel inhibitors for the treatment of immune diseases.